Ligand Preview: 56% Royalty Growth, One Report Away

Q2 results are Ligand's next major catalyst

Ligand reports second-quarter 2026 results on Thursday, August 6, 2026, with the conference call starting at 8:30 a.m. Eastern time. The timing matters because first-quarter royalty revenue already grew 56% year over year. After a jump like that, investors are likely to press management on whether the growth is becoming durable rather than remaining a one-quarter headline.

Ligand's model is straightforward: it funds late-stage biopharmaceutical programs and, in return, receives long-term economic interests in those assets. The company says it owns or manages economic interests in more than 200 development- and commercial-stage assets and also licenses its Captisol® and NITRICIL™ platforms. That setup is designed to produce multiple cash streams instead of relying on a single drug outcome.

With that backdrop, tomorrow's report is less about a single EPS print and more about whether Ligand is proving itself as a repeatable royalty portfolio rather than a collection of isolated upside stories.

What Q2 needs to confirm: durable royalties, not just one strong quarter

Ligand already demonstrated strong first-quarter royalty revenue growth. The next step is to show that the portfolio can keep converting diversification into revenue over time. In practical terms, investors want to see whether mature products, broader disease exposure, and a larger partner base are helping stabilize the model rather than simply creating a more complex story.

Royalty revenue is the clearest quality test

The most important read-through is the revenue mix. In the first quarter, Ligand generated $51.7 million in total revenue, including $43.0 million from royalties. If that royalty base continues to expand, it would suggest the existing portfolio is doing the heavy lifting. If growth leans more heavily on other parts of the business, the core royalty thesis may need more time to validate.

Management also linked first-quarter royalty strength mainly to Filspari, Ohtuvayre, and Capvaxive, while pointing to the full FDA approval of Filspari in focal segmental glomerulosclerosis as a milestone that strengthens a key royalty asset. That supports the view that Ligand's diversification is not just theoretical; some holdings are already advancing through meaningful commercial and regulatory checkpoints.

The XOMA acquisition should help scale the model, but it is not the proof point

This is where investor opinion is likely to diverge.

Organic momentum remains the more important test of durability. A royalty portfolio only looks like a repeatable engine if existing assets keep producing more cash without fresh deals. One quarter is suggestive, not conclusive.

The XOMA transaction is supportive, not a substitute for that evidence. Management said the deal is expected to add more than 120 commercial, clinical, and preclinical-stage assets, including seven commercial assets and 14 late-stage programs. That would deepen Ligand's diversification across therapeutic areas, development stages, and partners. But a larger portfolio does not automatically mean stronger current revenue, especially before closing.

Ligand also appears to have the balance-sheet flexibility to manage that expansion carefully. At the end of the first quarter, it held $779.4 million in cash, cash equivalents, and short-term investments.

What to watch on the call

• Royalty momentum: whether the revenue base is still growing at a strong clip and carrying most of the top-line gain.
• Asset concentration: whether Filspari, Ohtuvayre, and Capvaxive remain the main drivers, and whether other royalty contributors are starting to matter more.
• XOMA commentary: whether management frames the deal as a long-term diversification and growth accelerator while still emphasizing proof from the current portfolio.
• Guidance tone: whether management reinforces confidence in 2026 without relying too heavily on partial-year assumptions tied to XOMA.